MX2018014024A - Terapias de combinación con moduladores del receptor x farnesoide (fxr). - Google Patents
Terapias de combinación con moduladores del receptor x farnesoide (fxr).Info
- Publication number
- MX2018014024A MX2018014024A MX2018014024A MX2018014024A MX2018014024A MX 2018014024 A MX2018014024 A MX 2018014024A MX 2018014024 A MX2018014024 A MX 2018014024A MX 2018014024 A MX2018014024 A MX 2018014024A MX 2018014024 A MX2018014024 A MX 2018014024A
- Authority
- MX
- Mexico
- Prior art keywords
- inhibitor
- fxr
- farnesoid
- modulators
- receptor
- Prior art date
Links
- 102100038495 Bile acid receptor Human genes 0.000 title 1
- 101000603876 Homo sapiens Bile acid receptor Proteins 0.000 title 1
- 238000002648 combination therapy Methods 0.000 title 1
- 239000003112 inhibitor Substances 0.000 abstract 4
- 102000000452 Acetyl-CoA carboxylase Human genes 0.000 abstract 2
- 108010016219 Acetyl-CoA carboxylase Proteins 0.000 abstract 2
- 108010018763 Biotin carboxylase Proteins 0.000 abstract 2
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 abstract 1
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 abstract 1
- 102000011727 Caspases Human genes 0.000 abstract 1
- 108010076667 Caspases Proteins 0.000 abstract 1
- 229940127193 DGAT1 inhibitor Drugs 0.000 abstract 1
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 abstract 1
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 abstract 1
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 abstract 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 1
- 108010028924 PPAR alpha Proteins 0.000 abstract 1
- 102000023984 PPAR alpha Human genes 0.000 abstract 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 abstract 1
- 229940123518 Sodium/glucose cotransporter 2 inhibitor Drugs 0.000 abstract 1
- 102100039360 Toll-like receptor 4 Human genes 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 239000003613 bile acid Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000002604 chemokine receptor CCR2 antagonist Substances 0.000 abstract 1
- 239000003067 chemokine receptor CCR5 antagonist Substances 0.000 abstract 1
- 239000000841 delta opiate receptor agonist Substances 0.000 abstract 1
- 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 abstract 1
- 239000011734 sodium Substances 0.000 abstract 1
- 229910052708 sodium Inorganic materials 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
En la presente se describen métodos para tratar un trastorno metabólico en un individuo que lo necesita, que comprenden administrar de forma conjunta al individuo una cantidad terapéuticamente eficaz de un modular del FXR y al menos un segundo agente que es un antagonista de CCR2/CCR5, inhibidor de ASK1, inhibidor de DPP-IV, inhibidor de la proteasa de caspasa, inhibidor de SGLT2, inhibidor de acetil-CoA carboxilasa 8ACC), inhibidor de diacilgricerol aciltransferasa-1 inhibidor de cotrnsportadores de ácidos biliares sódicos, antagonista de TLR-4, agonista de PPAR alfa/delta, o agonista de GLP-1, o una combinación de estos.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662341482P | 2016-05-25 | 2016-05-25 | |
| US201662341487P | 2016-05-25 | 2016-05-25 | |
| PCT/US2017/034564 WO2017205684A1 (en) | 2016-05-25 | 2017-05-25 | Combination therapies with farnesoid x receptor (fxr) modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018014024A true MX2018014024A (es) | 2019-08-29 |
Family
ID=60412964
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018014024A MX2018014024A (es) | 2016-05-25 | 2017-05-25 | Terapias de combinación con moduladores del receptor x farnesoide (fxr). |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20200397798A1 (es) |
| EP (1) | EP3463373A4 (es) |
| JP (1) | JP2019517478A (es) |
| KR (1) | KR20190040936A (es) |
| CN (1) | CN109843298A (es) |
| AU (1) | AU2017270221A1 (es) |
| BR (1) | BR112018073460A2 (es) |
| CA (1) | CA3025007A1 (es) |
| IL (1) | IL263179A (es) |
| MX (1) | MX2018014024A (es) |
| RU (1) | RU2018145776A (es) |
| SG (2) | SG10202011660RA (es) |
| WO (1) | WO2017205684A1 (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201910332A (zh) * | 2017-06-02 | 2019-03-16 | 英商艾卡那治療有限公司 | 稠合的雙環化合物 |
| US11524029B2 (en) | 2018-08-13 | 2022-12-13 | Viscera Labs, Inc. | Therapeutic composition and methods |
| US11590161B2 (en) | 2018-08-13 | 2023-02-28 | Viscera Labs, Inc. | Therapeutic composition and methods |
| US20210322324A1 (en) * | 2018-08-14 | 2021-10-21 | Avolynt | Method for treating primary sclerosing cholangitis |
| WO2020081766A1 (en) * | 2018-10-18 | 2020-04-23 | Avolynt | Use of sglt2 inhibitors to treat primary sclerosing cholangitis |
| CN121081472A (zh) | 2018-12-13 | 2025-12-09 | 拓臻股份有限公司 | 一种THRβ受体激动剂化合物及其制备方法和用途 |
| CN111825653A (zh) * | 2019-04-19 | 2020-10-27 | 安道麦马克西姆有限公司 | 取代吡唑类化合物的制备及其作为邻氨基苯甲酰胺前体的用途 |
| AU2020336272A1 (en) | 2019-08-23 | 2022-04-14 | Terns Pharmaceuticals, Inc. | Thyroid hormone receptor beta agonist compounds |
| EP4028008A4 (en) | 2019-09-12 | 2023-09-13 | Terns Pharmaceuticals, Inc. | Thyroid hormone receptor beta agonist compounds |
| EP4061357A4 (en) * | 2019-11-22 | 2024-01-10 | Avolynt | Use of sglt2 inhibitors to treat primary billiary cholangitis |
| CA3168474A1 (en) * | 2020-03-11 | 2021-09-16 | Mi-Kyung Kim | Pharmaceutical composition for prevention or treatment of nonalcoholic steatohepatitis |
| US11478533B2 (en) | 2020-04-27 | 2022-10-25 | Novo Nordisk A/S | Semaglutide for use in medicine |
| US20220034871A1 (en) * | 2020-07-31 | 2022-02-03 | Daiichi Sankyo Company, Limited | Methods for administering pexidartinib |
| EP4204405A4 (en) | 2020-08-25 | 2024-05-29 | Eli Lilly and Company | POLYMORPHS OF AN SSAO INHIBITOR |
| WO2022127933A1 (zh) * | 2020-12-18 | 2022-06-23 | 深圳市绘云生物科技有限公司 | 新生儿胆道闭锁生物标志物的应用及检测方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1648408A4 (en) * | 2003-07-23 | 2006-11-29 | Exelixis Inc | AZEPINE DERIVATIVES AS PHARMACEUTICAL AGENTS |
| JP5081161B2 (ja) * | 2005-12-19 | 2012-11-21 | スミスクライン ビーチャム コーポレーション | ファルネソイドｘ受容体アゴニスト |
| EP3593802A3 (en) * | 2010-05-26 | 2020-03-25 | Satiogen Pharmaceuticals, Inc. | Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions |
| RU2723559C2 (ru) * | 2014-09-12 | 2020-06-16 | Тобира Терапьютикс, Инк. | Комбинированная терапия с применением препарата ценикривирок для лечения фиброза |
| MY192927A (en) * | 2014-11-21 | 2022-09-15 | Akarna Therapeutics Ltd | Fused bicyclic compounds for the treatment of disease |
| WO2016151403A1 (en) * | 2015-03-26 | 2016-09-29 | Akarna Therapeutics, Ltd. | Fused bicyclic compounds for the treatment of disease |
-
2017
- 2017-05-25 WO PCT/US2017/034564 patent/WO2017205684A1/en not_active Ceased
- 2017-05-25 MX MX2018014024A patent/MX2018014024A/es unknown
- 2017-05-25 JP JP2018562106A patent/JP2019517478A/ja active Pending
- 2017-05-25 CN CN201780045766.3A patent/CN109843298A/zh active Pending
- 2017-05-25 US US16/303,741 patent/US20200397798A1/en not_active Abandoned
- 2017-05-25 SG SG10202011660RA patent/SG10202011660RA/en unknown
- 2017-05-25 SG SG11201810290WA patent/SG11201810290WA/en unknown
- 2017-05-25 RU RU2018145776A patent/RU2018145776A/ru not_active Application Discontinuation
- 2017-05-25 AU AU2017270221A patent/AU2017270221A1/en not_active Abandoned
- 2017-05-25 BR BR112018073460A patent/BR112018073460A2/pt not_active Application Discontinuation
- 2017-05-25 CA CA3025007A patent/CA3025007A1/en not_active Abandoned
- 2017-05-25 KR KR1020187037471A patent/KR20190040936A/ko not_active Ceased
- 2017-05-25 EP EP17803627.3A patent/EP3463373A4/en not_active Withdrawn
-
2018
- 2018-11-21 IL IL263179A patent/IL263179A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3463373A1 (en) | 2019-04-10 |
| US20200397798A1 (en) | 2020-12-24 |
| KR20190040936A (ko) | 2019-04-19 |
| JP2019517478A (ja) | 2019-06-24 |
| IL263179A (en) | 2018-12-31 |
| RU2018145776A3 (es) | 2021-03-01 |
| CA3025007A1 (en) | 2017-11-30 |
| CN109843298A (zh) | 2019-06-04 |
| WO2017205684A1 (en) | 2017-11-30 |
| AU2017270221A1 (en) | 2018-12-20 |
| RU2018145776A (ru) | 2020-06-26 |
| EP3463373A4 (en) | 2020-04-22 |
| BR112018073460A2 (pt) | 2019-07-09 |
| SG11201810290WA (en) | 2018-12-28 |
| SG10202011660RA (en) | 2020-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018014024A (es) | Terapias de combinación con moduladores del receptor x farnesoide (fxr). | |
| MX2024001203A (es) | Combinaciones de agonistas de receptores de hormona tiroidea (tr-\03b2) con moduladores metabolicos para usarse en tratar enfermedades del higado graso. | |
| PH12019501010A1 (en) | Arginase inhibitor combination therapies | |
| EP4424364A3 (en) | Methods of treating liver disease | |
| PH12021551282A1 (en) | Radioimmunoconjugates and checkpoint inhibitor combination therapy | |
| MX2022009538A (es) | Nanoportadores sinteticos tolerogenicos y macromoleculas terapeuticas para efectos farmacodinamicos reducidos o intensificados. | |
| MX2019003364A (es) | Composiciones oftalmicas que comprenden ciclosporina. | |
| MX2024012816A (es) | Metodos para tratar y/o prevenir la enfermedad de injerto contra huesped y/o la hemorragia alveolar difusa y/o la enfermedad venooclusiva asociada al trasplante de celulas madre hematopoyeticas | |
| MX2020003959A (es) | Metodos terapeuticos relacionados con los inhibidores de hsp90. | |
| MA40437A (fr) | Méthodes de traitement du cancer faisant appel à des inhibiteurs de tigit et à des agents anticancéreux | |
| WO2018231905A8 (en) | Methods for treating myeloproliferative neoplasm-associated myelofibrosis and anemia | |
| ZA201906100B (en) | Combination of a ppar agonist with a fxr agonist | |
| MX2018010862A (es) | Tratamiento contra enfermedades autoinmunitarias con combinaciones de agonistas rxr y hormonas tiroideas. | |
| EP4324454A3 (en) | Cross-linking agents and associated methods | |
| MX2016010011A (es) | Metodos para tratar y prevenir trastornos renales y trastornos del higado graso. | |
| BR112019009726A2 (pt) | terapias combinadas para aterosclerose, incluindo doença cardiovascular aterosclerótica | |
| TW201613592A (en) | Glucose metabolism ameliorating agent | |
| PE20150020A1 (es) | Sistemas y metodos para tratar una respuesta farmacodinamica adversa inducida por opioides | |
| CL2019001014A1 (es) | Métodos de tratamiento de afecciones relacionadas con la inflamación utilizando moduladores metabólicos y anti inflamatorios pluripotentes. | |
| MX2021013354A (es) | Metodos para tratar y/o prevenir queratosis actinica. | |
| MX2015011386A (es) | Metodo para tratar cancer pancreatico. | |
| MX2018005352A (es) | Metodos y composiciones para el tratamiento de amiloidosis. | |
| MX2017016774A (es) | Agente terapeutico para la fibrosis. | |
| CL2015001448A1 (es) | Método para sincronización del tiempo de inseminación en cerdas jovenes | |
| MX2017007067A (es) | Administracion de un inhibidor selectivo de la trans-señalizacion de il-6. |